Life Extension and PIPA Screen 600,000 Molecules in 13 Weeks, Advance Five
Life Extension and PIPA say they screened about 600,000 natural molecules in a 13-week AI-driven collaboration and advanced five candidates to validation. The work used PIPA's Food Innovation Operating System (FIOS), and each candidate was already assessed for safety, sourcing feasibility and regulatory precedent, according to the companies.
- Life Extension and PIPA screened about 600,000 natural molecules in 13 weeks using PIPA's FIOS platform.
- 352 high-value bioactives were identified for scientific review, and five advanced to 60-to-90-day validation programs.
- Safety, sourcing and regulatory criteria were applied from the start rather than after candidate selection.
- According to the companies, fewer than one in 100,000 screened molecules reached the final five.
What the 13-week program found
Life Extension and PIPA announced the results of a discovery collaboration aimed at identifying a new generation of natural bioactive compounds with potential functional benefits. Using FIOS, the teams screened roughly 600,000 natural molecules across multiple biological pathways.
A total of 352 high-value bioactives were identified for scientific review. Five of them progressed to validation programs lasting 60 to 90 days, with predefined go/no-go criteria. According to the companies, fewer than one in 100,000 screened molecules advanced to the final five.
Each selected lead entered validation with a proposed mechanism of action and documented safety rationale. PIPA also said it benchmarked the screening system against established pharmacology before interpreting the new results.
Applying constraints first, not last
The companies describe a change in the order of work. Traditional supplement development is limited by how many compounds a research team can practically evaluate. Promising ingredients can also fail late in development because they cannot be sourced reliably, supported from a safety standpoint, or brought to market within regulatory requirements.
Rather than choosing a small set of ingredients first and dealing with commercial constraints afterward, Life Extension and PIPA screened the full compound space upfront. Safety, sourcing and regulatory criteria were applied from the beginning. PIPA evaluated hundreds of thousands of molecules across several biological mechanisms in parallel, filtering for practical development requirements before candidates reached Life Extension's scientists.
According to the announcement, this compresses a process that can traditionally take months or years into a single quarter, while giving scientists a much broader field of candidates.
Comments from both companies
Dr. Andrew Swick, Ph.D., Life Extension's Chief Science Officer, said: "AI-driven discovery enables us to evaluate a far broader universe of natural compounds with the scientific rigor Life Extension is known for." He added that integrating safety, sourcing and regulatory considerations from the start lets the company focus on candidates with real-world potential.
Eric Hamborg, CCO of PIPA, said: "FIOS searches far wider and asks the safety, regulatory, and sourcing questions first." He said Life Extension's scientists worked on the strongest candidates instead of spending months narrowing the field.
The companies involved and what comes next
Life Extension has operated since 1980 and offers vitamins, nutritional supplements and blood-testing services. PIPA describes itself as an AI systems company for food intelligence, serving food, nutrition and ingredient companies across the product development lifecycle. Its platforms include LEAP, for scientific discovery and ingredient innovation, and FIOS.
The announcement presents the result as a model for ingredient discovery in which a brand can search an entire compound space, rule out unsafe or unviable candidates before the lab, and reach validation in a single quarter. The five candidates have not yet completed validation, so their functional benefits remain to be confirmed in the 60-to-90-day programs. The release does not name the compounds or give a timeline for any products.
